Inmagene enrolls first patient in ADAPTIVE phase 2b clinical trial of IMG-007: San Diego Friday, July 4, 2025, 15:00 Hrs [IST] Inmagene Biopharmaceuticals (Inmagene), a clinical-s ...

AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

AbbVie has announced a definitive agreement to acquire Capstan Therapeutics, a clinical-stage biotechnology company, for up ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...

WASHINGTON (dpa-AFX) - Biopharmaceutical company AbbVie, Inc. (ABBV) and privately-held clinical-stage biotechnology company Capstan Therapeutics, Inc., announced Monday a definitive agreement ...

Sigvotatug Vedotin is an ADC that targets integrin αvβ6-positive tumor cells. It has an engineered antibody that ensures high ...

I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

The growing prevalence of chronic diseases is a major factor driving revenue growth in the natural killer (NK) cell ...

Plants produce a wide diversity of compounds. Broadly, these are separated into primary metabolites, which are necessary for ...